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http://dx.doi.org/10.1016/j.stemcr.2017.01.012SUMMARYThe truncatedmutant form of the chargedmultivesicular body protein 2B (CHMP2B) is causative for frontotemporal dementia linked to
chromosome 3 (FTD3). CHMP2B is a constituent of the endosomal sorting complex required for transport (ESCRT) and, when mutated,
disrupts endosome-to-lysosome trafficking and substrate degradation. To understand the underlying molecular pathology, FTD3 patient
induced pluripotent stem cells (iPSCs) were differentiated into forebrain-type cortical neurons. FTD3 neurons exhibited abnormal endo-
somes, as previously shown in patients. Moreover, mitochondria of FTD3 neurons displayed defective cristae formation, accompanied by
deficiencies inmitochondrial respiration and increased levels of reactive oxygen. In addition, we provide evidence for perturbed iron ho-
meostasis, presenting an in vitro patient-specific model to study the effects of iron accumulation in neurodegenerative diseases. All phe-
notypes observed in FTD3 neurons were rescued in CRISPR/Cas9-edited isogenic controls. These findings illustrate the relevance of our
patient-specific in vitro models and open up possibilities for drug target development.INTRODUCTION
Frontotemporal dementia (FTD) is the second most com-
mon form of early-onset (<65 years) dementia, accounting
for 5%–8% of total dementia cases. FTD is a neurodegener-
ative disorder with cognitive impairment affecting the
frontal and/or temporal lobes of the brain associated with
progressive brain atrophy (Rossor et al., 2010). FTD is clin-
ically, neuropathologically, and genetically heterogeneous.
One gene affected in familial cases is the charged multive-
sicular body protein 2B (CHMP2B) located on chromosome
3 (FTD3). Patients display global cortical and central brain
atrophies, with no apparent amyloid plaque formation or
conclusive hyperphosphorylated tau aggregates (Isaacs
et al., 2011). Early behavioral changes include apathy, rest-
lessness, disinhibition, and hyperorality. Late-stage behav-
ioral changes include stereotype behavior, mutism, and
dystonia (Isaacs et al., 2011). CHMP2B is a component of
the endosomal sorting complex required for transport III648 Stem Cell Reports j Vol. 8 j 648–658 j March 14, 2017 j ª 2017 The Aut
This is an open access article under the CC BY-NC-ND license (http://creativ(ESCRT-III) complex, which facilitates recycling or degrada-
tion of cell surface receptors (Chassefeyre et al., 2015). As
such, the FTD3-causing mutation of CHMP2B affects func-
tionality of the endosome. Mouse andDrosophila FTD3 an-
imal models have yielded valuable in vivo insights into the
dysfunction of the endosomal lysosomal system and path-
ologic progression (Ahmad et al., 2009; Ghazi-Noori et al.,
2012). However, transgene integration and species-specific
differencesmay contribute to observed phenotypes in such
models. Hence, there is an emerging need for human FTD3
models. In addition, studying how CHMP2B, as a rare mu-
tation, contributes to neurodegenerative disorders has not
yet attracted broader attention. Consequently, a CHMP2B
mutant cellular model could provide further insights into
common underlying dysfunction of biological pathways,
disrupted or disturbed in neurodegenerative diseases and
thereby linking different forms of neurodegeneration.
The availability of viable neurons from patient brains, at
least in part, limits the investigation of the mechanism ofhor(s).
ecommons.org/licenses/by-nc-nd/4.0/).
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neurodegenerative pathogenesis. In this context, human-
induced pluripotent stem cells (iPSCs) provide invaluable
access to study the disease progression in neurons derived
from patient iPSCs and facilitate the development of new
therapies (Ehrlich et al., 2015; Rasmussen et al., 2014).
Meanwhile, recent advances of state-of-the-art genome en-
gineering technique CRISPR/Cas9 (Ran et al., 2013) have
had a tremendous impact allowing for gene correction in
patients who are carriers of disease-causing single-point
mutations. Such genetically edited iPSCs are ideal isogenic
controls for the patient-derived iPSCs, allowing to precisely
dissect the significance of the disease-causing mutation
while maintaining the patient’s own genetic background.
To study the cellular and molecular events of FTD3,
we derived a disease model using human iPSCs from
patients carrying the 31449G > C mutation in CHMP2B
and isogenic controls generated via the CRISPR/Cas9
system with subsequent in vitro neuronal differentiation.
Our model not only confirmed partly prior-observed
pathologies in animal models such as endosome dysregu-
lation (Ghazi-Noori et al., 2012), but also revealed addi-
tional disease-relevant phenotypes in FTD3 by way of
abnormal mitochondrial ultrastructure and function.
Moreover, RNA sequencing (RNA-seq) uncovered that
the CHMP2B mutation manifests in dysregulated expres-
sion of key genes associated with Parkinson’s disease (PD)
and Alzheimer’s disease (AD) and indicated that per-
urbed iron homeostasis is one of the underlying disease
mechanisms.RESULTS
Generation of FTD3 iPSCs and Genetically Corrected
Isogenic Controls
Skin fibroblasts from two symptomatic FTD3 patients
(H150 and H151) and one presymptomatic FTD3 patient
(H242)were reprogrammedusingnon-integrative episomal
plasmids. All of these individuals are from the same family,
and one independent healthy control from an unrelated
family was also included. Individual FTD3 iPSC lines were
assessed for pluripotency features via qPCR (Figure S1A)Figure 1. Gene Correction of FTD3 iPSCs, In Vitro Neuronal Differ
(A) CRISPR/Cas9-mediated gene correction of CHMP2B 31449G > C, s
tification of CHMP2B mutant and wild-type mRNA transcripts. The ex
expression values of wild-type which was set to 100%.
(B) Schematic of neuronal differentiation protocol (see Experiment
fibroblast growth factor; GDNF, glial cell line-derived neurotrophic fa
(C) Quantification of TUJ1, VGlut1, and FOXG1 mRNA expression le
(H150 ISO, H151 ISO, H242 ISO). n = 3 with three replicates in each ex
lines.
(D) Morphometric analyses in FTD3 neurons and isogenic controls: Aver
experiment, significant differences are indicated by *p < 0.05 and **
650 Stem Cell Reports j Vol. 8 j 648–658 j March 14, 2017and immunocytochemistry (ICC) (Figure S1B). Assessment
of pluripotencypotentialwas confirmedvia embryoidbody
formation and subsequent spontaneous differentiation
(Figure S1C). The FTD3-causing mutation 31449G > C
(located at the splice acceptor site inCHMP2B, at the border
of intron 5 and exon 6) was repaired in the FTD3 iPSC lines
using the CRISPR/Cas9 system (Figure 1A). The presence of
altered CHMP2BmRNA, as formerly shown in Urwin et al.
(2010) was confirmed via qPCR and showed expression of
the intron 5 and delta-10 isoforms only in the patient
iPSC. These abnormal transcripts, generated via the
CHMP2B mutation affecting the slice acceptor site, are
completely absent in the isogenic controls (Figure 1A). All
iPSC and genetically corrected isogenic lines were deter-
mined to be karyotypically normal (Figure S1D).Differentiation of FTD3 iPSCs to Forebrain Cortical
Neurons
We employed a modified dual SMAD protocol (Figure 1B)
to generate forebrain-specific cortical neurons. Flow cy-
tometry analyses demonstrated the neural progenitor cell
(NPC) cultures to be comparable with respect to NESTIN
and SOX1 expression (Figure S2A). All NPCs expressed
the forebrain markers PAX6 and OTX2 (Figure S2B). ICC
revealed the majority of the matured neurons to be gluta-
matergic (immunopositive for VGlut1 [Figure S2C] and
co-positive for MAP2, TAU, and TUJ1 [Figure S2C]).
Approximately 10% of neurons were GABAergic (Fig-
ure S2C), while approximately 5% were GFAP-positive as-
trocytes, with a minor population (2%–3%) comprising
tyrosine hydroxylase-positive dopaminergic neurons (Fig-
ure S2C). Since quantification via ICC is challenging we
performed qPCR for TUJ1, VGlut1, and FOXG1 in order to
estimate the comparability in regard to the neural cell
composition of the investigated FTD3 iPSC- and isogenic
iPSC-derived neurons. All lines showed comparable
amounts of expression with no significant differences,
which is also indicative that the mutation in CHMP2B
does not affect the differentiation potential toward neu-
rons (Figure 1C). Neurons exhibited spiking activity and
action potentials, which occurred both spontaneouslyentiation, and Morphometric Analyses
sODN with silent mutation (SacII), sequencing results, and quan-
pression values were calculated as relative amount of mRNA versus
al Procedures for details). Scale bar, 200 mm for all. BFGF, basic
ctor; cAMP, cyclic AMP.
vels in FTD3 neurons (H150, H151, H242) and isogenic controls
periment, no significant differences were found among the different
age neurite length and soma size. n = 3 with three replicates in each
*p < 0.001.
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and under current-clamp conditions (Figures S3B–S3D).
Measurement of intracellular calcium levels also demon-
strated that cultures exhibited neuronal functionality.
The neurons were responsive to the neurotransmitters
glutamate/glycine, GABA, and, to a lesser extent, acetyl-
choline (Figure S3A), and depolarization of the plasma
membrane by addition of potassium resulted in a small in-
crease in intracellular calcium (Figure S3A). Serotonin and
dopamine did not induce a change in intracellular calcium
levels. All lines showed similar responses.
FTD3 Neurons Display Aberrant Endosomes
Via transmission electron microscopy, we observed simi-
larly enlarged endosome (assessed as endosome-occupied
relative neuronal area, see the Supplemental Experimental
Procedures) in our FTD3 neurons, as previously demon-
strated in patients (Urwin et al., 2010) (Figure 2A). Such
enlarged endosomes were absent from the isogenic con-
trols, indicating a rescue of the phenotype by CRISPR/
Cas9-mediated gene correction and is consistent with pre-
vious knockdown experiments (Nielsen et al., 2012). Spe-
cifically, the electron-lucent and, thus, vacant endosomes
were significantly more abundant in the FTD3 neurons
(Figures 2B and 2C), indicative of an effect on early-stage
endosomes.
FTD3 Neurons Display Abnormal Mitochondria
Given that mitochondrial defects are commonly observed
in neurodegenerative diseases, we assessed whether such
a phenotype is evident in FTD3 neurons. While we noted
no apparent difference in size of mitochondria between
FTD3 neurons and their isogenic controls, we did observe
a significant increase in abnormal mitochondria with se-
vere impairment of cristae formation in FTD3 neurons
(Figures 2E and 2F). Strikingly, the distribution of mito-
chondria within neurons was also perturbed in FTD3 neu-Figure 2. FTD3 Neurons Exhibit Aberrant Endosome and Mitochon
(A and B) Stereology and ultrastructure of endosome in FTD3 neurons
control (black bar): (A) shows total size of endosome; (B) shows the ra
into electron-lucent (Endo L), medium electron-dense (Endo M), a
experiment, significant differences are indicated by *p < 0.05. n.s., n
(C) Transmission electron microscopy (TEM) images of Endo L, Endo M
(D) Total number of endosome-associated genes and the top ten differ
discovery rate (FDR) of 5%.
(E) Stereology and ultrastructure of mitochondria in FTD3 neurons (r
control (black bar): relative size of mitochondria compared with cyto
chondria; n = 3 with three replicates in each experiment, significant
(F) TEM images of normal and cristaeless mitochondria. Scale bar, 1 m
(G) Images of neurons dyed with the mitochondrial probe MitoTracke
mitochondria and the dashed line shows a representative distribution o
(H) Total number of mitochondria-associated genes and top ten diffe
FDR of 5%.
652 Stem Cell Reports j Vol. 8 j 648–658 j March 14, 2017rons: MitoTracker analyses revealed mitochondria in FTD3
neurons to preferentially localize to the perinuclear region,
while isogenic controls exhibited a homogeneous distribu-
tion throughout axons and dendrites (Figure 2G). Consis-
tent with previous studies correlating a lack of axonalmito-
chondria with axonal degradation (Rawson et al., 2014), we
also observed disorganized microtubule organization in
FTD3 neurons (Figure S4A). These findings were substanti-
ated by the fact that the average neurite length and soma
size were significantly reduced in FTD3 neurons versus
isogenic controls (Figure 1D).
FTD3 Neurons Display Impaired Mitochondria
Function and Increased Oxidative Stress
Prompted by our observations of aberrant mitochondrial
morphology, we sought to test the functionality of such
FTD3 mitochondria by assessing their basal respiration
rate, ATP-linked respiration, proton leak, and reserve ca-
pacity. Our analyses uncovered a reduced basal respiration
rate in FTD3 neurons as well as a reducedmaximal capacity
(Figure 3E). Consistent with mitochondrial dysfunction
manifesting in oxidative stress, we observed up to 20%
occurrence of oxidative stress in FTD3 neurons compared
with only 7% in isogenic controls (Figure 3A). Thus,
FTD3 neurons are exposed to higher levels of oxidative
stress, and targeted gene editing can reverse the disease
phenotype. Subsequently, we investigated whether the
increased oxidative stress impacts cell viability, but we de-
tected no evidence for increased apoptosis in FTD3 neu-
rons (Figure 3B).
Global Gene Expression Analyses Confirm Defects in
the Endosome, Mitochondrial Dysfunction, and
Increased Oxidative Stress
To obtain an overview of gene expression changes in
CHMP2B-dependent neurodegeneration, we performeddria
(red bar), isogenic controls (gray bar), and an independent healthy
tio of endosome to cytoplasm and further subdivision by appearance
nd electron-dense (Endo D); n = 3 with three replicates in each
ot significant.
, and Endo (D) Scale bar, 1 mm for all.
entially expressed genes (on the basis of fold-change) within a false
ed bar), isogenic controls (gray bar), and an independent healthy
plasmic area of all mitochondria (Mito total) and cristaeless mito-
differences are indicated by **p < 0.01, and ***p < 0.001.
m for both.
r (red) counterstained with DAPI (blue). Arrowheads indicate dyed
fmitochondria in an isogenic control neuron. Scale bar, 10mm for all.
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RNA-seq analyses, which revealed 3,205 differentially ex-
pressed genes in FTD3 neurons compared with their
isogenic controls. Heatmap analyses showed that neurons
derived from iPSCs of all three FTD3 individuals clustered
together, while isogenic controls clustered together with
the independent healthy individual (Figure 4A), suggesting
that the isogenic control lines reverted to a healthy control
gene expression profile after repair of the CHMP2B muta-
tion. To identify which cellular components are primarily
affected in FTD3 neurons, we performed gene ontology
(GO) term analysis. We found enrichment of the GO term
for postsynaptic membrane, synaptic membrane, neuron
projection, and synaptic vesicle membrane (Figure 4C),
and depletion of early endosome membrane, lysosomal
lumen, and endocytic vesicle membrane (Figure 4D).
With the aim to identify additional genes associated
with the main phenotypes observed in FTD3 neurons, we
extracted the top ten differentially regulated genes func-
tionally linked to neurodegeneration and associated with
endosomes (Figure 2D), mitochondria (Figure 2H), and
oxidative stress (Figure 3C). Strikingly,APOE ranked among
the ten most downregulated endosome-associated genes
(Figure 2D). APOE4, an isoform of APOE, is a well-known
risk factor for sporadic AD (sAD) (Corder et al., 1993) and,
consistent with a putative role in FTD3 pathophysiology,
some sAD patients present with enlarged early endosomes
(Cataldo et al., 2000).
Most interestingly, we observed an upregulation of
leucine-rich repeat kinase 2 (LRRK2) among the mitochon-
dria-related genes (Figure 2H). LRRK2 is one of the five
genes mutated in familial forms of PD. Previous studies
reported mitochondrial fragmentation due to increased
expression of LRRK2 (Wang et al., 2012), pointing to an
association between upregulated LRRK2 expression and
cristae dysgenesis in FTD3 neurons. LRRK2 was also de-
tected in the oxidative stress group (Figure 3C) and is upre-
gulated in some cases of sporadic PD (Cho et al., 2013)
accompanied by elevated levels of oxidative stress (Nguyen
et al., 2011). MPO and APOD, both implicated in AD (Fig-
ure 3C) (Maki et al., 2009; Martinez et al., 2012), were
strongly downregulated in FTD3 neurons.Figure 3. Impaired Mitochondrial Function and Oxidative Stress i
(A) CellROX green and SYTOX red flow cytometry assay of live oxidativ
significant differences are indicated by **p < 0.01 and ***p < 0.001
(B) CellEvent Caspase-3/7 green and SYTOX red flow cytometry assay
(C) Total number of oxidative stress-associated genes and the top ten
an FDR of 5%. n.s., not significant.
(D and E) Mitochondrial function profile of FTD3 neurons (H150, H151
(D) oxygen consumption rate (OCR) was measured before (basal) an
(trifluoromethoxy)phenylhydrazone (FCCP), and a mixture of rotenon
respiration parameters were calculated based on the OCR measurem
Procedures. n = 3 with three replicates in each experiment, significant
654 Stem Cell Reports j Vol. 8 j 648–658 j March 14, 2017Imbalance of Iron Homeostasis Represents a Unifying
Factor Linking Endosome, Mitochondrial
Dysfunction, and Oxidative Stress
Via our in silico analyses, we identified mis-expression of
genes encoding proteins or receptors known to be involved
in iron homeostasis. Among these were TRPC6 (12-fold up-
regulated), HFE (8-fold downregulated), and ABCG2, HP,
and CP (all 2-fold downregulated) (Figure 4B). A potential
imbalance of iron homeostasis might plausibly induce
intracellular ferrous iron (Fe2+) accumulation, damaging
mitochondria and inducing stress, to be further exacer-
bated by the defects in the endosome compartment
contributing to increased amounts of trapped Fe3+ within
endosomes (Figure 4E). Supporting this hypothesis, cyto-
plasmic Fe2+ levels are significantly increased in FTD3
neurons versus isogenic control neurons (Figure 4F). This
increase in intracellular iron was consistent in several
independent neural differentiation experiments, and the
increased expression in TRCP6was also confirmed viawest-
ern blot analysis (Figure 4B), further substantiating our hy-
pothesis for impaired iron homeostasis triggered by altered
expression and protein amounts of key regulators.
Taken together we have shown that FTD3 neurons have
enlarged early endosomes, display mitochondria dysfunc-
tion and perturbed iron homeostasis, with subsequent in-
crease in oxidative stress.DISCUSSION
The biological function of CHMP2B has primarily been
investigated in animal models, with the attendant caveat
that observed phenotypes are potentially species specific
or contributed to by transgene integration. Here, to pre-
clude such issues, we developed an FTD3 patient-derived
disease model by way of iPSCs generation, genome editing,
and in vitro neuronal differentiation techniques.
We identified enlargements of particularly the early endo-
some population in FTD3 neurons, indicating that per-
turbed endo-lysosomal fusion anddegradationof substrates
is key to the underlying FTD3 pathophysiology. Cellularn FTD3 Neurons
e stressed neurons. n = 3 with three replicates in each experiment,
.
of apoptotic neurons.
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ents shown in (D) as described in the Supplemental Experimental
differences are indicated by *p < 0.05, **p < 0.01, and ***p < 0.001.
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components, including mitochondria, are degraded in the
endosome; in amyotrophic lateral sclerosis, a progressive
lysosomal deficit is causative for impaired degradation of
damaged mitochondria in motor neurons (Xie et al.,
2015). Defective recycling of large organelles, such as mito-
chondria, is the earliest detectable impairment in a chain of
events initiated by defective recycling (Cannizzo et al.,
2012), which clearly links endosome and mitochondrial
dysfunction.
FTD3 neurons displayed abnormal mitochondrial locali-
zation and cristae formation, manifesting in impaired
functionality typical for neurodegenerative diseases. Defec-
tive mitochondria show impaired ATP generation and
release of deleterious chemicals such as reactive oxygen
species (ROS), potentially inducing cell death. We contend
that increased ROS release contributes to increased organ-
elle damage, which cannot be appropriately ameliorated
through degradation owing to the observed endosome
defects, resulting in a self-perpetuating cycle of cellular
damage.
Strikingly, in FTD3 neurons we identified a robust, signif-
icant upregulation of LRRK2 encoding the dardarin pro-
tein. One function of dardarin is the modulation of
intracellular trafficking via recruitment of RAB7 (Greggio
et al., 2006). Mutant CHMP2B impairs the recruitment of
RAB7, crucial for endosome-lysosome fusion (Urwin
et al., 2010). This relationship between CHMP2B, RAB7,
and dardarin is supported by studies showing that dardarin
negatively regulates RAB7-dependent localization of the
lysosome (Dodson et al., 2012). Therefore, upregulation
of LRRK2 as a consequence of CHMP2B mutation might
contribute to deficient endo-lysosomal trafficking and
fusion. Dardarin also plays a role in mitochondrial func-
tionality and positioning, since induced expression of
wild-type LRRK2 induces mitochondrial fragmentation via
increased fission and upregulation of DLP1, which is crit-
ical for correct mitochondrial distribution (Wang et al.,
2012).
Furthermore, our analysis revealed APOE to be signifi-
cantly downregulated in FTD3 neural cells. The cells
analyzed via RNA-seq are a mixed population of neurons
and glial cells, with an up to 90% enrichment of VGlut1+Figure 4. Transcriptional Analysis of FTD3 Neurons Versus Isogen
(A) Heatmap and hierarchical clustering analysis of gene expression
(H150 ISO, H151 ISO, H242 ISO) as well as one independent healthy
(B) qPCR validation of genes of interest from RNA-seq results and we
(C and D) GO term enrichment analysis of differentially expressed gene
as nodes linked based on their kappa score level (R0.5), where only
size represents the term enrichment significance. Functionally relate
(E) Diagram of key dysregulated genes involved in intracellular iron h
(F) Fe2+ assay and concentration normalized to total cellular protein.n
are indicated by *p < 0.05.
656 Stem Cell Reports j Vol. 8 j 648–658 j March 14, 2017neurons. Due to this mixed population of cells we were still
able to detect APOE via RNA-seq, even though it is mainly
expressed in astrocytes. APOE is a major cholesterol carrier
in neurons that supports lipid transport and brain injury
repair, and there is a key requirement for APOE in facili-
tating the clearance of soluble amyloid beta (Abeta) (Jiang
et al., 2008). Furthermore, APOE suppresses microglia acti-
vation (Laskowitz et al., 2001), and reduced APOE levels
might potentially trigger inflammatory events. Together,
this suggests that downregulation of APOE in FTD3 neu-
rons might be a contributing factor in the microglia activa-
tion seen in postmortem FTD3 brains. Interestingly, we
observed another phenotype restricted to glial cells. It has
previously been reported for FTD3 mouse models and
patient brains that these display p62 inclusions, which
are indicative for impaired autophagy, oxidative stress,
and neurotoxicity (Ghazi-Noori et al., 2012; Holm et al.,
2007). We identified these p62 inclusions only in the
S100b+ glial cell population and not in our TUJ1+ neurons
(Figure S4B). Both the APOE and the p62 phenotypes
clearly show that, even though several disease features
can be replicated in our FTD3 neurons, other neural cell
types need to be investigated in the future to understand
the full complexity and pathophysiology of the disease.
Based on the differentially expressed key components
and increase of intracellular iron in FTD3 neurons, we pre-
sent an additional pathological feature of FTD3, which is
associated with an imbalance in iron homeostasis (Fig-
ure 4E). Iron uptake principally proceeds through iron
bound to transferrin mediated via the transferrin receptor
or via direct uptake of Fe2+ facilitated by a variety of recep-
tors including TRPC6 (Mwanjewe and Grover, 2004). We
propose that upregulation of TRPC6manifests in increased
uptake of Fe2+, while downregulation of HFE (which com-
petes with Tf), results in uptake of more ferric iron which
can further be reduced into Fe2+. In contrast, export of
heme-bound iron via ABCG2 or unbound Fe2+ through
FPN can be reduced. Concordant with this model, we
confirmed in several individual differentiation experi-
ments a small but significant increase of intracellular iron
within 5 weeks of neuronal differentiation in FTD3 neu-
rons. Excessive amounts of intracellular Fe2+ are toxic toic Controls and Quantification of Intracellular Fe2+ Content
profile of FTD3 neurons (H150, H151, H242) and isogenic controls
control (H256).
stern blot relative quantification of TRPC6 protein expression.
s via ClueGO v1.4 software. Functionally grouped network with terms
the label of the most significant term per group is shown. The node
d groups partially overlap.
omeostasis.
= 3 with three replicates in each experiment, significant differences
cells and trigger the production of ROS. Moreover, Fe2+ and
hydrogen peroxide engage in the so-called Fenton reaction,
producing ferric iron and highly reactive hydroxide, which
damages DNA, proteins, and lipids in the cell (Altamura
and Muckenthaler, 2009).
FTD3 neurons present with enlarged early endosomes,
increased cristaeless mitochondria, intracellular iron accu-
mulation, and oxidative stress. All of these phenotypes
were rescued via genetic correction of the CHMP2B
mutation.
We propose that in FTD3 neurons two events occur in
parallel: (1) mutant CHMP2B causes an imbalance in iron
homeostasis triggering mitochondrial impairment, which
consequently triggers ROS and neuronal damage, and (2)
mutant CHMP2B-dependent enlargement of endosomes,
which causes defects of the endo-lysosomal degradation
and recycling pathway, including recycling of receptors
for iron uptake, results in accumulation of defective
mitochondria, imbalanced iron homeostasis, ROS, and
neuronal damage. Future studies will determine the exact
role of mutant CHMP2B on a molecular level within these
cellular events.
In conclusion, our findings indicate a possibility of tar-
geting iron imbalances therapeutically in efforts to inter-
vene in this cycle of damage to attempt treatment of
FTD3. Furthermore, the CHMP2B-dependent human
iPSC-derived neurons can be added to the list of in vitro
cellular model systems that serve as a tool to study not
only common mechanisms of pathogenesis, such as mito-
chondrial defects and oxidative stress, but also the effects
of iron accumulation in neurodegenerative diseases.EXPERIMENTAL PROCEDURES
Cell Culture, iPSC Generation, and Neuronal
Differentiation
iPSCs were generated via episomal reprogramming (Addgene,
27077, 27078, 27080) from human dermal fibroblasts obtained
from skin biopsies. Neuronal differentiation followed a modified
dual SMAD protocol.Genome Editing
Generation of isogenic controls from the three FTD3 iPSC lineswas
achieved via the CRISPR/Cas9 system (Addgene, 62988) using sin-
gle-strand donor oligonucleotides as a template.Transmission Electron Microscopy
Cells were seeded on 13 mm Thermanox plastic coverslips
(Nunc, 174950) coated with poly-O-Lysine/laminin. Ultra-thin
(50–70 nm) sections were prepared, contrasted with 2% uranyl
acetate (PolyScience, 21447) and lead citrate, and examined us-
ing a Philips CM100 transmission electron microscope equipped
with a Morada camera.RNA-Seq Analysis
For deep RNA-seq, libraries of FTD3neurons, isogenic controls, and
an independent healthy controlwere prepared and sequenced on a
HiSeq 2000 Sequencing System (Illumina) following the manufac-
turer’s protocol.
Statistical Analysis
Data are presented as mean ± SE. n is the number of independent
differentiations of NPCs (from the cryobank) to neurons. Signifi-
cance of data was evaluated by Student’s t test or two-way
ANOVA with Bonferroni post hoc test. Unless noted otherwise,
p < 0.05 was considered statistically significant.
For further details on Experimental Procedures, see the Supple-
mental Information.
ACCESSION NUMBERS
The RNA-seq data described in this study have been deposited in
the NCBI GEO database under accession number GEO: GSE92340.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, four figures, and one table and can be found with
this article online at http://dx.doi.org/10.1016/j.stemcr.2017.
01.012.
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 SUPPLEMENTAL FIGURE LEGENDS 
Figure S1. Basic Characterisation of iPSCs, Related to Figure 1. (A) qPCR analysis of 
pluripotency genes in FTD3 iPSCs relative to H1 human ESCs. (B) ICC of FTD3 iPSCs for 
pluripotentcy marker proteins. Scale bars, 200 μm for all. (C) ICC of FTD3 iPSCs with βIII-
TUBULIN (ectoderm), α-SMA (mesoderm), and AFP (endoderm) after EB differentiation. Scale 
bar, 200 μm for all. (D) Karyotype analysis of FTD3 iPSCs and isogenic controls showing no 
abnormalities. 
 
Figure S2. Forebrain Identity of NPCs and Differentiation into Cortical Neurons, Related to 
Figure 1. (A) Flow cytometry assay for NESTIN and SOX1 in the FTD3 NPCs and isogenic 
controls. (B) Immunocytochemistry (ICC) assay of NPCs for NESTIN and forebrain progenitor 
protein markers OTX2 and PAX6. Scale bar, 50 μm. (C) ICC confocal images of FTD3 neurons 
and isogenic controls: dendritic neuronal protein marker MAP2 coupled with axonal protein marker 
TAU, glial marker GFAP, cortical markers TBR1 and CTIP2, axonal neuronal protein marker TUJ1 
coupled with glutamatergic neuron marker VGLUT1, GABAergic neuron marker GABA and 
dopaminergic marker TH. Scale bars, 50 μm for all and 15 μm for TUJ1 coupled with VGLUT1. 
 
Figure S3. Functional Characterization of Cortical Neurons, Related to Figure 1. (A) 
Intracellular calcium kinetics in FTD3 neurons (H150, H151, H242) and isogenic controls (H150 
ISO, H151 ISO, H242 ISO). (B), (C), (D) and (E) Electrophysiological properties of FTD3 neurons 
and isogenic controls: (B) action potentials activated by current steps; (C) spontaneous elicited 
action potentials; (D) whole-cell currents activated by a series of voltage steps: in some recordings, 
excitatory postsynaptic potentials (EPSP) were observed at negative potentials as demonstrated in 
the enlarged portion of the recording; (E) representative image of patched cells. Scale bar, 300 μm 
 for all. 
 
Figure S4. TEM Overview Image of Neurons and p62 Aggregates Characterization in the 
Neural Culture, Related to Figure 2-4. (A) Images represent initial segment of an axon and a 
portion of the nucleus. In the FTD3 neurons, endosome-like structures (*) and mitochondria (x) 
accumulate, and the arrangement of microtubule structures (indicated by triangle arrow) is 
perturbed compared with isogenic controls. Scale bar, 2 μm for all. (B) Immunostaining for p62 and 
the neuronal marker protein TUJ1, glial maker protein S100β in FTD3 neural cultures and isogenic 
control. Red box indicates area with cells having p62 positive aggregates. DAPI was used a nuclear 
marker. Scale bar, 20 μm for all. 
 Table 1A 
Summary of Characterization of All hiPSC Lines Used in The Current Study 
hiPSC Line Genotype Karyotype Pluripotency-associated Marker Gender 
H150 G/C 31449 in CHMP2B Normal + M 
H151 G/C 31449 in CHMP2B Normal + M 
H242 G/C 31449 in CHMP2B Normal + F 
H150 ISO Gene correction Normal + M 
H151 ISO Gene correction Normal + M 
H242 ISO Gene correction Normal + F 
H256 C6 Wild-type Normal + M 
 
Table 1B 
Primers for qPCR 
Gene Name Gene ID (GI) Forward Reverse 
OCT4 553727227 CCCCAGGGCCCCATTTTGGTACC 
ACCTCAGTTTGAATGCATGG
GAGAGC 
SOX2 325651854 TTCACATGTCCCAGCACTACCAGA 
TCACATGTGTGAGAGGGGCA
GTGTGC 
NANOG 663071048 AAAGAATCTTCACCTATGCC GAAGGAAGAGGAGAGACAGT 
GDF3 10190669 TGACCATCTCCCTCAACAGC TACCCACACCCACACTCATC 
TRPC6 170014741 ATCCAGTCATGACGGCTTTAG TCTGCACAGATCAAGGAGTC 
HFE 91718876 TGTTCACTGTTGACTTCTGGAC 
ATCATACCCGTACTTCCAGT
AG 
HO-1 298676487 ATGGAGCGTCCGCAACCCGAC 
TGAAGCCGTCTCGGGTCACC
TG 
ABCG2 62526032 ACAGCTTCCAATGACCTGAA GTTGAGACCAGGTTTCATGA
 GG TC 
FLVCR2 190341090 ACATTGAAGACCGGGACGAGC 
TCAAGGCATAGCTCAGGGAT
TG 
CP 189458860 TGGGATTATGCCTCTGACCATG 
AGGTTTCATCTGTGTACTGA
AG 
HP 531034758 ACTCGTCCCTATACCATCCAC 
TTCTGGAATGGTCCAGTTGT
AG 
APOE 705044057 TGGTCACATTCCTGGCAGGATG 
TAATCCCAAAAGCGACCCAG
TG 
LRRK2 171846277 TCACGTACTCCGAGCGCGCCTC 
CTGCTGCACACTCGCGACTC
TC 
GAPDH 576583510 ACCACAGTCCATGCCATCAC TCCACCACCCTGTTGCTGTA 
EIF6A 392494081 AAGTCTTCAGACAGACAGTGGCCGACCAG 
ACCACCATCCCAGCAGCAAT
CACCT 
CHMP2B 170650589 Common forward primer: GACATCTTTGACGGTTCTGA  
CHMP2B   Wild-type specific reverse primer: GAGCTTTGGCCATCTTTC 
CHMP2B   
Intron5 specific reverse primer: 
GAAAAGATGATGTTCATACC
TTTC 
CHMP2B   Delta10 specific reverse primer: CAGCTGATGGAGCTTTCC 
 
Table 1C 
List of Antibodies 
Antibody Name Diliution Vendor and Catalog Number 
OCT4 1/500 Santa Cruz, sc-8628 
NANOG 1/500 Peprotech, 500-P236 
SSEA4 1/100 Biolegend, 330402 
TRA-1-60  1/200 Biolegend, 330602 
TRA-1-81 1/200 Biolegend, 330702 
 NESTIN 1/1000 Millipore, MAB5326 
OTX2 1/500 R&D, AF1979 
PAX6 1/300 Covance, PRB-278P 
MAP2 1/500 Sigma, M1406 
TUJ1 1/500 Covance, MRB-435P 
TAU 1/200 Dako, A0024 
GFAP 1/400 Dako, Z0334 
TBR1 1/300 Abcam, ab31940 
CTIP2 1/200 Abcam, ab28448 
VGLUT1 1/500 Synaptic Systems, 135303 
GABA 1/200 Sigma, A2052 
TH 1/500 Pel-Freez Biologicals, P40101-0 
S100β 1/1000 Abcam, ab11178 
P62 1/200 Progen, GP62-C 
TRPC6 1/1200 Alomone Labs, ACC-017 
β-Actin 1/5000 Sigma, A5441 
IRDye® 680LT 1/15000 LI-COR, 926-68023 
IRDye® 800CW 1/15000 LI-COR, 32212 
 
SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
Ethical Statement 
The study was approved by the Ethics Committee of the Capital Region of Denmark 
(H-4-2011-157), and written informed consent was obtained from each participant before 
enrollment. 
 
Cell Culture, iPSC Generation and Neuronal Differentiation 
Human dermal fibroblasts cultures were obtained from skin biopsies from two symptomatic (H150, 
H151) and one presymptomatic (H242) FTD3 individuals (all from the same family), as well as one 
healthy unrelated individual (H256). The FTD3 individuals were carriers of the G-to-C transition at 
the 5´ acceptor splice site of CHMP2B exon 6 on chromosome 3 (Skibinski et al., 2005). Fibroblasts 
were cultured in DMEM supplemented with 1% GlutaMAXTM, 10% FBS and 1% 
Penicillin-Streptomycin. For the generation of iPSCs, one microgram of reprogramming plasmid 
mixtures was electroporated into 1 × 105 fibroblasts using the Neon® transfection system (Thermo 
Fisher Scientific, USA) with a 10μL kit according to the manufacturer’s instructions. The plasmid 
mixtures used in this experiment were pCXLE-hOCT3/4, pCXLE-hSK and pCXLE-hUL (Addgene, 
27077, 27078, 27080) (Okita et al., 2011). Electroporation conditions were as followed: 1,200 V, 20 
ms, 2 time pulses. After transfection, 5 × 104 cells were distributed onto 35-mm dishes coated with 
Matrigel (BD Biosciences, USA) and cultured in DMEM, 1% GlutaMAXTM, 10% FBS without 
bFGF and Penicillin-Streptomycin. The culture medium was replaced the next day and 
supplemented with bFGF, Penicillin-Streptomycin and cultured at 5% O2, 5% CO2 and 90% N2. On 
day 3 to 4 depending on confluence, the culture medium was replaced with ESC medium consisting 
of Essential 8TM basal medium with supplement (Thermo Fisher Scientific, A1517001), 100 μM 
Sodium Butyrate and 0.1% Penicillin-Streptomycin. The colonies were manually picked 21–28 d 
after plating, and those colonies morphologically similar to human embryonic stem cells (ESCs) 
were selected for further cultivation and evaluation. When confluent, iPSC were passaged 1:3-6 
with 0.5 mM EDTA on to VitronectinTM (Thermo Fisher Scientific, A14700)-coated 6-well dishes. 
The hiPSC clones used in this study are summarized in Table S1A. Mutation status was confirmed 
by Sanger sequencing. 
iPSC lines were differentiated toward neural-specific progenies in 6-well plate wells (NUNC, 
USA) pre-coated with Matrigel® (BD Biosciences, 354277) in a 21% O2 5.0% CO2 37°C incubator 
employing a modified dual SMAD protocol (Shi et al., 2012). Cells were expanded in E8 medium 
until around 100% confluence was reached. Neural induction was initiated by changing the medium 
to neural basic medium consisted of 50% DMEM/F-12 medium, 50% Neural basal medium 
(Thermo Fisher Scientific, 10888-022), N2 (Thermo Fisher Scientific, 17502-048), B27 without 
Vitamin A (Thermo Fisher Scientific, 12587-010), supplemented with SB431542 a small molecule 
inhibitor of the TGFß pathway (Selleck, S1067) and LDN193189 an inhibitor of the BMP pathway 
(Selleck, S2618). The duration of this initial neural induction was 10 to 12 days. Subsequently, cells 
were split onto poly-O-Lysine/laminin (Sigma, L2020) pre-coated 6-well plate wells and remained 
in the neural induction medium overnight. Expansion of the neural progenitor cells, for 
cryopreservation and subsequent terminal differentiation was achieved by proliferating these cells 
in neural basic medium supplemented with 10 ng/ml bFGF. Neuronal maturation was achieved by 
addition of the following media: Neural basic medium supplemented with 20 ng/ml BDNF (Cell 
Guidance Systems, GFH1-10), 10 ng/ml GDNF (Cell Guidance Systems, GFH2-10), 50 μM 
db-cAMP (Sigma, D0627) and 200 μM L-Ascorbic acid 2-phosphate (Sigma, A8960). One week 
after terminal differentiation cells were replated again for further maturation. 
 
Genome Editing  
Generation of isogenic controls was achieved via the CRISPR/Cas9 system using single-strand 
donor oligonucleotides (ssODNs) as templates for single nucleotide repairs.  
Isogenic gene-corrected controls were obtained using the CRISPR/Cas9 system in combination 
with ssODNs as homologous templates covering the mutation site. The ssODNs were designed with 
silent mutations that both prevent recutting of the CRISPR/Cas9 and create a restriction enzyme 
recognition site for SacII to enable screening for recombinant clones. The CRISPR/Cas9 vectors 
were generated following the protocol from Ran et al. (Ran et al., 2013). At a confluency of 80%, 
the iPS cells growing in a 10-cm plate were incubated with Accutase for 5 – 10 minutes at 37 °C. 
iPS cells were harvested and centrifuged. 2 million cells were co-transfected with 10 µg of the 
CRISPR/Cas9 plasmid (Addgene, 62988) and 1 µL of 100 ng/µL of the ssODNs. We used a 4D 
nucleofector (program CA167) from Amaxa in combination with the P3 Primary Cell Kit for 
transfection. Transfected cells were plated on a 10 cm dish coated with Matrigel. After one day, 
Puromycin (Thermo Fisher Scientific, A1113803) was added for 2 days in a 1:50000 dilution. After 
selection, Puromycin was withdrawn. Around 4 - 8 days after selection, resistant iPS colonies were 
picked and transferred to a cell culture 96 well plate. When the wells became confluent, iPS cells 
were split into a DNA isolation plate and a 96 well cell culture dish for further cultivation. DNA 
was isolated using the prepGEMTM Kit (zyGEM, PTI0500). Subsequently, a PCR was performed 
with primer pair P1-FW and P1-RV. PCR products were digested with SacII for 30 – 60 minutes at 
37 °C. Positive clones were sequenced to confirm gene-editing of CHMP2B. 
 
Quantitative qPCR 
RNA was extracted using RNeasy® Plus Mini Kit (Qiagen, 74134) according to the 
manufacturer’s protocol. cDNA was synthesized from 1 μg of total RNA in 20 μL reaction using 
iScript™ cDNA synthesis Kit (BIO-RAD, 1708890). After synthesis, the cDNA was diluted five 
times with double distilled water and stored at −20 °C. Quantitative RT-PCR (qPCR) reactions 
were done in triplicates using the FastStart Lightcycler 480 SYBR Green I Master (Roche, 
04707516001) on LightCycler® 480 real-time PCR system (Roche, Switzerland). cDNA samples 
were subjected to PCR amplification with primers for OCT4, SOX2, NANOG, GDF3 and GAPDH 
(Table S1B). A commercial ESCs line H1 (Wicell, USA) was used as a positive control. 
 
Quantification of CHMP2B RNA Transcripts 
Half a microgram of RNA was subjected to first strand synthesis using random hexamer primers 
and SuperScript III Reverse Transcriptase (Invitrogen) in accordance with the manufacturer’s 
instructions. PCR reactions were assembled using 5 µl of Brilliant III ultra-fast SYBR Green 
qPCR master mix (Agilent Technologies), 0.5 µl of forward primer (10 µM 0.5 µl of reverse 
primer (10 mM), 2 µl of water, and 2 µl of cDNA template. The PCR program was as follows: 2 
min at 50˚C, 10 min at 95˚C and then 40 cycles of 15 s at 95˚C, 30 s at 58-60˚C (dependent on 
primers) and 1min at 72˚C. To distinguish the three different isoforms of CHMP2B, a common 
forward primer was used with either one of the three isoform specific reverse primers. The 
sequences of the primers were listed in Table S1B. For normalization, primers detecting the 
housekeeping gene EIF6 were used. CHMP2B specific primers were used at an annealing 
temperature of 58˚C, whereas the EIF6A primer pair was used at 60˚C. 
The relative abundance of the CHMP2B WT transcript between the different cell lines was 
calculated by normalization to EIF6 employing the relative standard curve method. The relative 
abundance of the three different isoforms of CHMP2B within each cell line was calculated by 
constructing standard curves from serial dilutions of a single plasmid holding all three amplicons in 
a stoichiometry of 1:1:1. This way we were able to calculate the exact amount of each isoform in 
relation to one another within in each cell line using the relative standard curve method. 
 Immunocytochemistry and Confocal Microscopy 
For the immunofluorescence staining, cells were fixed with 4% formaldehyde in Dulbecco's 
Phosphate-Buffered Saline (DPBS) for 15 min, permeabilized with 1% Triton X-100 in DPBS for 
15 min, and blocked with 2% bovine serum albumin in DPBS for 1 h. Thereafter, cells were 
incubated with the following primary antibodies (Table S1C) for 1 h. Primary antibodies were 
detected using secondary antibodies conjugated to Alexa Fluor 488 (1:500; Molecular Probes), 
Alexa Fluor 594 (1:500; Molecular Probes) and Alexa Fluor 647 (1:500; Molecular Probes). Cells 
were washed in DPBS and stained with DAPI (Sigma-Aldrich, D9542). Fresh DPBS was 
replaced and cells were imaged immediately using sequential line scanning with a Leica TCS SP5 
II inverted CLSM or Z-stack recording with a Zeiss LSM 710 CLSM equipped with UV laser, 
Argon laser and AOBS beam splitter. 
 
Flow Cytometry 
To verify purity and similar proportions of marker positive hNPCs from each differentiated cell 
line, intracellular markers of hNPCs were analyzed by flow cytometry. When the hNPCs reached 
80%–90% confluence, cells were dissociated using TrypLETM Express (Thermo Fisher Scientific, 
12605010) and incubated with Fixation/Permeabilization Working Solution (eBioscience, 
88-8824) at room temperature for 60 mins. After centrifuging, the supernatant was discarded and 
cell pellets were resuspended in 1× Permeabilization Buffer containing monoclonal antibodies 
against NESTIN (BD Pharmingen, 560393) and SOX1 (BD Pharmingen, 561592). After 45 min 
of incubation in the dark at room temperature, cells were washed with fresh 1× Permeabilization 
Buffer, and resuspended in Flow Cytometry Staining Buffer (eBioscience, 00-4222) at a density 
of 1×106 cells/ml. Subsequently, they were analyzed by the CSampler™ Flow Cytometer (BD 
Accuri™, USA). Unlabeled samples were used as controls for gating. Data was analyzed using the 
FlowJo software (version 10.0). 
 
Whole-cell Patch Clamp Recording 
Whole-cell current-clamp and voltage-clamp measurements were performed on FTD3 neurons 
and isogenic controls after terminal differentiation from hNPCs for 5 weeks by using a 
MultiClamp 700B amplifier and MultiClamp Commander (Axon Instruments, Molecular Devices, 
USA). Patch pipettes were fabricated from borosilicate glass capillaries (1.5mm O.D., Fisher 
Scientific) on a gravity puller (Model PP-830, Narishige, Japan) and had a final tip resistance of 
2–3 MΩ. Recordings were performed at 36±1̊ C in extracellular solution containing (in mM): 
NaCl, 125; HEPES, 10; NaH2PO4, 1.25; MgCl2, 1; CaCl2•2H2O, 2; glucose, 25; pyruvic acid, 3 
(pH 7.4, 290 mOsm) and patch pipettes were filled with intracellular solution containing (in mM): 
K-gluconate, 135; NaCl, 7; MgCl2, 2; HEPES, 10; Na2-ATP, 2; Na2-GTP, 0.3 (pH 7.2, 270 
mOsm). The recording conditions were modified from Shi et al., 2012 (Shi et al., 2012). 
Spontaneous mini excitatory/inhibitory postsynaptic or action potential activity was monitored for 
1 min. The membrane potential was adjusted to approximately -60 mV followed by stepwise 
current injections from 0 pA to +50 pA. Voltage-clamp recordings were performed from a 
holding potential of −110 mV. Currents were activated by a series of depolarizing steps ranging 
from −90 mV to +30 mV. All analog signals were acquired at 50 kHz, filtered at 6 kHz, digitized 
with a Digidata 1440 converter (Axon Instruments, Molecular Devices) and stored using 
pClamp10 software (Axon Instruments, Molecular Devices). Recordings were corrected for a −14 
mV junction potential and data were analyzed using Clampfit 10 software (Axon Instruments, 
Molecular Devices). 
 
Recordings of Intracellular Calcium Kinetics   
Recordings of intracellular calcium kinetics were performed on FTD3 neurons and isogenic 
controls after terminal differentiation from hNPCs for 5 weeks. Neurons cultured in 96-well 
plates were loaded for 1 h at 37°C with 100 μL of the fluorescent calcium indicator, Calcium 5 
(Molecular Devices, USA) dissolved in Hanks Balanced Salt Solution (HBSS; Thermo Fisher 
Scientific) with 20 mM HEPES and 1.26 mM CaCl2 to 1/3 of the concentration suggested by 
provider. Recordings were performed at 37°C in a FDSS 7000 fluorescence kinetics plate reader 
(Hamamatsu Photonics, Japan). The excitation wavelength was 480 nm; the emission wavelength 
was 540 nm and the sampling frequency 1 Hz. Compound dilutions were prepared in assay buffer 
and 20 μl applied with 10 min intervals. Baseline fluorescence was recorded for 10 min before 
application of 300 μM glutamate/10 μM glycine, 100 μM Serotonin (5-hydroxytryptamine, 5-HT), 
25 mM K+, 100 μM GABA , 100 μM Dopamine (DA), and 300 μM acetylcholine (Ach). The 
fluorescence was normalized to the first data point of each of the traces. 
 
Morphometric Analyses 
Images of beta tubulin III-immunoreactive cells were recorded (12 images/cell line) using a bright 
field microscope (×200) connected to a digital camera (Leica). Average neurite length and soma 
size were assessed on coded images (experimenters ´blinded´ to sample identity) using the 
software ImageJ (version 1.50e) and the plugin NeuronJ (version 1.4.3). Only cells displaying an 
intense beta tubulin III immunostaining and a neuronal morphology (well-preserved cell soma 
and ≥ 1 primary neurite) were included in the analyses. Results are expressed as mean values ± 
SEM from 129-515 neurons per cell line. 
 
Transmission Electron Microscopy 
Cells were seeded on 13 mm Thermanox™ plastic coverslips (NUNC, 174950) coated with 
poly-O-Lysine/laminin. Cells were fixed with 3% glutaraldehyde (Merck, 1042390250) in 0.1 M 
Na-phosphate buffer, pH 7.4, post-fixed in 1% osmium tetroxide in 0.1 M Na phosphate buffer, 
dehydrated stepwise in a graded ethanol series, and embedded in Epon (TAAB, T031). Semi-thin 
(2 μm) sections were cut with a glass knife (KnifeMaster II, LKB Bromma 7800) on an 
ultramicrotome (Leica Ultracut, Leica Microsystems, Wetzlar, Germany), stained firstly with 1% 
toluidine blue O (Millipore, 1159300025) and 1% Borax (LabChem, LC117101). Ultra-thin (50 
nm to 70 nm) sections were sectioned with a diamond knife (Jumdi, 2 mm) on an ultramicrotome 
(Leica Ultracut), contrasted with 2% uranyl acetate (Polyscience, 21447) and lead citrate, and 
examined using a Philips CM100 transmission electron microscope equipped with a Morada 
camera. 
 
Oxidative Stress Assay 
Reactive oxygen species (ROS) production was quantified in FTD3 neurons and isogenic controls 
using CellROX® Green Flow Cytometry Assay kit (Thermo Fisher Scientific, C10492). Staining 
was carried out according to the manufacturer’s instructions, and stained cells were dissociated 
from the plate using Accutase and immediately analyzed by flow cytometry using CSampler™ 
Flow Cytometer (BD Accuri™, USA).  
 
Apoptosis Assay 
Activated Caspases 3 and 7 in apoptotic cells was quantified in FTD3 neurons and isogenic controls 
using CellEvent® Caspase-3/7 Green Flow Cytometry Assay kit (Thermo Fisher Scientific, 
C10427). Staining was carried out according to the manufacturer’s instructions, and labeled cells 
were dissociated from the plate using Accutase and immediately analyzed by flow cytometry using 
CSampler™ Flow Cytometer (BD Accuri™, USA).  
 
Seahorse XFe96 Mitochondria Respiration Assay 
Oxygen consumption rate (OCR) was measured using a Seahorse XFe96 Extracellular Flux 
Analyzer (Seahorse Biosciences, USA). FTD3 hNPCs and isogenic controls were seeded in a 
Seahorse 96-well cell culture microplate at a density of 6.5×103 cells/well for neuronal maturation. 
On the day of the assay, the culture media was changed to unbuffered DMEM (pH 7.4) 
supplemented with 2.5 mM glucose and the cells were equilibrated for 10 min at 37 oC in a 
CO2-free incubator. The pH of the reagents used to test mitochondrial function was adjusted to 
7.4 on the day of assay. The OCR measurement cycle consisted of 3-min mix and 3-min 
measurement of the oxygen level. Test of mitochondrial function was initiated by three baseline 
OCR measurement cycles. These were followed by the sequential injection of the inhibitor of 
ATP synthase, Oligomycin (2 µM final concentration); the uncoupling agent, Carbonyl cyanide 
4-(trifluoromethoxy)phenylhydrazone (FCCP, 1 µM); a mixture of the inhibitors of mitochondrial 
complexes I and III, Rotenone (0.5 µM) and Antimycin A (0.5 µM) with one OCR measurement 
cycle in between each injection and two final measurement cycles. Oxygen consumption rates 
were automatically recorded and calculated by the Seahorse XFe 96 software, Wave. Subsequent 
to the Seahorse analysis, the protein content was measured for each well using the Pierce assay 
with bovine serum albumin as standard. Results are expressed as mean values ± SEM from 12 
wells/plate obtained in triplicate for each condition. Mitochondrial respiration parameters were 
calculated as follows: basal respiration, non-mitochondrial respiration (minimum measurement 
after rotenone/antimycin injection) was subtracted from the last measurement obtained before 
oligomycin injection; proton leak, non-mitochondrial respiration was subtracted from the 
measurement after oligomycin injection; maximal respiration, measurement obtained after FCCP 
injection; spare respiratory capacity, basal respiration subtracted from maximal respiration; ATP 
production, measurement after oligomycin injection was substracted from the last measurement 
before oligomycin injection. 
 
MitoTracker ® Assay 
Cells for MitoTracker® Red CMXRos (Molecular Probes, M7512) analysis were cultured on 0.17 
μm glass coverslips coated with poly-O-Lysine/laminin. When ready for staining, cells were 
incubated with 50 nM MitoTracker® in DMEM/F-12 medium for 15 min in 37 °C. Following, 
fixation in 4% paraformaldehyde in DPBS, permeabilization in 0.5% Triton X-100 in DPBS for 
15 min, incubation with DAPI for 10 min in room temperature. In between each step the samples 
were washed 3 times in DPBS. After the last wash, the glass coverslips were mounted with 
mounting media and sealed onto slides. Images were acquired by laser scanning confocal 
microscopy (Zeiss LSM 710). 
 
RNA Sequencing Analysis 
For deep RNA sequencing, libraries of FTD3 neurons, isogenic controls and one independent 
healthy control were prepared and sequenced independently on HiSeq 2000 Sequencing System 
(Illumina, USA). For library construction, after extracting the total RNA from samples, mRNA 
and non-coding RNAs are enriched by removing rRNA from the total RNA with kit. By using the 
fragmentation buffer, the mRNAs and non-coding RNAs are fragmented into short fragments 
(about 200-500 nt), then the first-strand cDNA is synthesized by random hexamer-primer using 
the fragments as templates, and dTTP is substituted by dUTP during the synthesis of the second 
strand. Short fragments are purified and resolved with EB buffer for end reparation and single 
nucleotide A (adenine) addition. After that, the short fragments are connected with adapters, then 
the second strand is degraded using UNG(Uracil-N-Glycosylase) finally. For data processing, 
Illumina Casava1.8 software was used for base calling. Clean reads were obtained by filtering 
reads with adaptor sequences and low quality reads. Clean reads that aligned to rRNA were 
removed. After removing reads aligned to rRNA, we used SOAP2 to align clean reads to the hg19 
UCSC RefSeq (RNA sequences, GRCh37) (para: -m 0 -x 1000 -s 40 -l 32 -v 5 -r 2 -p 4). Gene 
level expression was performed by transforming uniquely mapped transcript reads to TPM. 
Normalized differentially expressed genes were detected. Genes whose expression changes are 
more than 1.5 folds with FDR < 5% identified in FTD3 neurons compared to isogenic controls 
were submitted to Gene ontology (GO) enrichment analysis. GO enrichment analysis of 
assembled transcripts was performed with ClueGO v1.4 (Bindea et al., 2009) using the following 
parameters: use GO term fusion; enrichment/depletion two-sided hypergeometric statistical test; 
correction method: Benjamini-Hochberg; GO term range levels: 3-8; minimal number of genes 
for term selection: 10; minimal percentage of genes for term selection: 10%; κ-score threshold: 
0.5; general term selection method: smallest p value; group method: κ; minimal number of 
subgroups included in a group: 3; minimal percentage of shared genes between subgroups: 50%. 
For qPCR validation of the RNA sequencing results, we performed independent neuronal 
differentiation experiments and examined key gene expression, and all primer sequences for these 
genes are listed in Table S1B. 
 
Western Blotting 
Cell pellets from FTD3 neurons and isogenic controls were lysed in mPER™ mammalian protein 
extraction reagent (Thermo Fisher Scientific, 78501) containing protease inhibitor (Complete 
tablets, Roche 11873580001) and phosphatase inhibitors (PhosSTOP tablets, Roche 
04906845001). 10 μg of protein were separated by NuPAGE™ Novex™ 4-12 % Bis-Tris mini gel 
(Thermo Fisher Scientific, NP0335BOX) followed by immunoblotting with rabbit anti-TRPC6 
(Alomone Labs, ACC-017) and mouse anti-ß-Actin (Sigma, A5441) primary antibodies, 
donkey-anti-rabbit IRDye® 680LT (LI-COR, 926-68023) and donkey-anti-mouse IRDye® 
800CW (LI-COR, 32212) secondary antibodies. Immunoblots were developed by Odyssey® Fc 
Imaging System (LI-COR) and data was processed using the software ImageStudio version 5.2.5. 
Expression levels of TRPC6 were normalized to ß-Actin. 
 
Ferrous Iron Assay 
Cell pellets were obtained from FTD3 neurons and isogenic controls. An iron assay kit (Abcam, 
ab83366) was subsequently used to quantify ferrous iron (Fe2+) in the neurons according to 
manufacturer's instructions. Briefly, cell pellets were homogenized with 120 µL iron assay buffer 
and supernatants were collected. 20 µL cell supernatant was used for the assay and volume was 
adjusted to 100 µL with iron assay buffer. Then, 100 µL of the iron probe solution was added 
producing a Fe2+-Ferene S complex that absorbs light at 593 nm. Infinite® 200 PRO Multimode 
Reader (TECAN, Switzerland) was used to detect absorbance at this wavelength. 
 
Statistical Analysis 
Data are presented as mean ± standard errors (S.E.). “n” is the number of independent 
differentiations of NPCs (from the cryobank) to neurons. Significance of data was evaluated by 
Student’s t test or two-way ANOVA with Bonferroni post hoc test. Unless noted otherwise, P<0.05 
was considered statistically significant.
Supplemental References 
Bindea, G., Mlecnik, B., Hackl, H., Charoentong, P., Tosolini, M., Kirilovsky, A., Fridman, W.H., 
Pages, F., Trajanoski, Z., and Galon, J. (2009). ClueGO: a Cytoscape plug-in to decipher 
functionally grouped gene ontology and pathway annotation networks. Bioinformatics 25, 
1091-1093. 
Okita, K., Matsumura, Y., Sato, Y., Okada, A., Morizane, A., Okamoto, S., Hong, H., Nakagawa, 
M., Tanabe, K., Tezuka, K., et al. (2011). A more efficient method to generate integration-free 
human iPS cells. Nat Methods 8, 409-412. 
Ran, F.A., Hsu, P.D., Wright, J., Agarwala, V., Scott, D.A., and Zhang, F. (2013). Genome 
engineering using the CRISPR-Cas9 system. Nat Protoc 8, 2281-2308. 
Shi, Y., Kirwan, P., and Livesey, F.J. (2012). Directed differentiation of human pluripotent stem 
cells to cerebral cortex neurons and neural networks. Nat Protoc 7, 1836-1846. 
Skibinski, G., Parkinson, N.J., Brown, J.M., Chakrabarti, L., Lloyd, S.L., Hummerich, H., Nielsen, 
J.E., Hodges, J.R., Spillantini, M.G., Thusgaard, T., et al. (2005). Mutations in the endosomal 
ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet 37, 806-808. 
